Laennec (Laennec)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbspinjection
Composition:In 2 ml of the drug contains 112 mg of human placental hydrolyzate, water for injection,pH corrector (sodium hydroxide or hydrochloric acid).
Description:

Transparent liquid from light yellow to brown color, with a characteristic odor.

Pharmacotherapeutic group:Hepatoprotective agent
ATX: & nbsp
  • Preparations for the treatment of liver diseases
    • Pharmacodynamics:

    Laennek exhibits immunomodulatory properties due to the ability to stimulate a humoral immunity and increases the functional activity of phagocytes and natural killer cells; increases the bactericidal activity of peripheral blood leukocytes, manifested in their ability to destroy the captured pathogen. Cytokines, which are part of the drug, activate the metabolic and surveillance functions of skin cells. Biologically active substances in the hydrolyzate stimulate regeneration (proliferation) hepatocytes exhibit detoxification properties, reduce deposition of lipid and cholesterol in hepatic cells, enhance the activity of tissue respiration, activate the metabolism in the liver reduce the intensity of the connective tissue in the liver.

    Indications:

    The drug is used in the complex therapy of the following diseases: chronic recurrent herpes, atopic dermatitis of moderate and severe course (including complicated).

    In the form of monotherapy for chronic liver diseases: steatohepatitis (alcohol, metabolic and mixed etiology).

    Contraindications:

    Hypersensitivity, child age, pregnancy, lactation.

    Carefully:

    With caution should be used in patients with polyvalent allergy to drugs, as well as in the elderly.

    Pregnancy and lactation:

    The use of the drug during pregnancy and breastfeeding is contraindicated.

    Dosing and Administration:

    With chronic recurrent herpes and atopic dermatitis:

    - intravenous drip introduction: 10 ml (540 mg of placental hydrolyzate) of the drug (5 ampoules) are dissolved in 250-500 ml of a 5% solution of dextrose or saline and injected through the ulnar vein for 1.5-2 hours. Injections are carried out 3 times a week with an interval of 2 days. The course of treatment is 10 injections.

    With chronic liver disease: steatohepatitis (alcoholic, metabolic and mixed etiology):

    - intramuscularly: 2 ml per day (112 mg of placental hydrolyzate).Depending on the severity of the disease, the frequency of injections can be increased up to 2-3 times (up to 6 ml) per day;

    - intravenous drip introduction: 10 ml (560 mg of placental hydrolyzate) of the drug (5 ampoules) are dissolved in 250-500 ml of a 5% solution of dextrose or saline and injected through the ulnar vein for 1.5-2 hours. Injections are carried out daily. The course of treatment is 2-3 weeks.
    Side effects:

    It is noted in 3.7% of patients.

    Clinically significant adverse reactions

    Allergic reactions are possible, including anaphylactic shock.

    Other undesirable phenomena

    Soreness at the injection site

    2,56%

    Allergic reactions (redness, itching of the skin)

    0,37%

    Injection at the injection site

    0,37%

    Gynecomastia (causal relationship with the introduction of the drug is not established)

    0,37%
    Overdose:

    At present, no cases of an overdose of Laennec were reported.

    Interaction:

    When Laennec confused with other drugs that are strong bases (pH above 8.5), as a result of pharmaceutical interaction, its activity decreases.

    No other clinically relevant interactions of Laennec have been reported to date.

    Special instructions:

    Use of the drug in children

    Studies on the safety of the use of Laennec in preterm infants, newborns and infants have not been conducted. Use in children is not recommended.

    Application of the drug in the elderly

    According to the data currently available, the elderly age is not a contraindication for the appointment of Laennec. Nevertheless, since the physiological functions of the elderly are deteriorating, the use of the drug must be carefully controlled.

    Effect on the ability to drive transp. cf. and fur:

    Influence on the ability to drive vehicles, mechanisms is not established.

    Form release / dosage:Injection.
    Packaging:

    2 ml in ampoules of dark glass of hydrolytic class 2; each ampoule has a spot of white, indicating the place of breaking the ampoule.

    10 or 50 ampoules per cardboard bundle with cardboard partitions with instructions for use.

    Packing for hospital: 200 ampoules in a cardboard bundle with cardboard partitions with instructions for use.

    Storage conditions:

    At a temperature of 18 to 25 ° C, in a place protected from light.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:П N013851 / 01
    Date of registration:24.10.2008 / 27.11.2015
    Expiration Date:Unlimited
    The owner of the registration certificate:Medical Corporation RANA, LLC Medical Corporation RANA, LLC Russia
    Manufacturer: & nbsp
    Representation: & nbspClinic RANA LLC Clinic RANA LLC Russia
    Information update date: & nbsp09.02.2018
    Illustrated instructions
      Instructions
      Up